<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39545343</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Molecular Analysis of Coxsackievirus B2 Associated With Severe Symptoms of the Central Nervous System.</ArticleTitle><Pagination><StartPage>e70066</StartPage><MedlinePgn>e70066</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.70066</ELocationID><Abstract><AbstractText>Coxsackievirus B2 (CVB2) is a member of the enterovirus group known to induce a spectrum of illnesses, from mild to severe. In the summer of 2022, an unusual outbreak of enteroviral central nervous system (CNS) infections occurred that was attributed to CVB2. Cerebrospinal fluid (CSF) samples collected from patients in 2015-2022 were tested for enterovirus via RT-PCR, followed by Sanger sequencing for positive cases. CVB2 samples were further sequenced in the P1 region using NGS. A total of 30 CSF samples were identified as CVB2, with 60% of these cases occurring between June and August 2022. The 2022 CVB2 variants were associated with severe clinical symptoms, including encephalitis (50%) and ataxia (27.8%). Samples from 2015 to 2020 were also included due to the absence of these symptoms. Phylogenetic analysis revealed that CVB2 strains from 2019 to 2020 were also distinct from those obtained in 2022. Amino acid analysis of the capsid proteins VP1, VP2, and VP3 identified three unique substitutions with potential antigenic significance in the 2022 variant: S67A in VP2, and T93A and E274D in VP1. These substitutions were not present in earlier strains or reported in the literature, suggesting they may influence the virus's virulence. The clinical observations from this study highlight new patterns of CVB2 infection in the CNS that had not been previously observed. Additionally, it identifies unique genetic changes in the 2022 CVB2 variant that may account for the increased virulence seen in the 2022 outbreak. However, further analysis is required to validate this assumption.</AbstractText><CopyrightInformation>Â© 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fratty</LastName><ForeName>Ilana S</ForeName><Initials>IS</Initials><Identifier Source="ORCID">0000-0001-7414-8022</Identifier><AffiliationInfo><Affiliation>Central Virology Laboratory, Public Health Services, Ministry of Health and Sheba Medical Center, Ramat-Gan, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Israel Center for Disease Control, Israel Ministry of Health, Ramat-Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kriger</LastName><ForeName>Or</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Microbiology, Sheba Medical Center, Ramat-Gan, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sheba Medical Center, Pediatric Infectious Disease Unit, Ramat-Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Leah</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Central Virology Laboratory, Public Health Services, Ministry of Health and Sheba Medical Center, Ramat-Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasserman</LastName><ForeName>Rinat</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Central Virology Laboratory, Public Health Services, Ministry of Health and Sheba Medical Center, Ramat-Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabai</LastName><ForeName>Reut</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Central Virology Laboratory, Public Health Services, Ministry of Health and Sheba Medical Center, Ramat-Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erster</LastName><ForeName>Oran</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Central Virology Laboratory, Public Health Services, Ministry of Health and Sheba Medical Center, Ramat-Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S Zuckerman</LastName><ForeName>Neta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Central Virology Laboratory, Public Health Services, Ministry of Health and Sheba Medical Center, Ramat-Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glatman-Freedman</LastName><ForeName>Aharona</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Israel Center for Disease Control, Israel Ministry of Health, Ramat-Gan, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lustig</LastName><ForeName>Yaniv</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Central Virology Laboratory, Public Health Services, Ministry of Health and Sheba Medical Center, Ramat-Gan, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sofer</LastName><ForeName>Danit</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Central Virology Laboratory, Public Health Services, Ministry of Health and Sheba Medical Center, Ramat-Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weil</LastName><ForeName>Merav</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Central Virology Laboratory, Public Health Services, Ministry of Health and Sheba Medical Center, Ramat-Gan, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>The authors received no specific funding for this work.</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="Y">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="Y">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="Y">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coxsackievirus B2</Keyword><Keyword MajorTopicYN="N">encephalitis</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">meningitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>16</Day><Hour>22</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>15</Day><Hour>5</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39545343</ArticleId><ArticleId IdType="doi">10.1002/jmv.70066</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>R. S. Machado, F. N. Tavares, and I. P. Sousa Jr., âGlobal Landscape of Coxsackieviruses in Human Health,â Virus Research 344 (2024): 199367.</Citation></Reference><Reference><Citation>L. Brouwer, G. Moreni, K. C. Wolthers, and D. Pajkrt, âWorldâWide Prevalence and Genotype Distribution of Enteroviruses,â Viruses 13, no. 3 (2021): 434.</Citation></Reference><Reference><Citation>E. Heckenberg, J. T. Steppe, and C. B. Coyne, âEnteroviruses: The Role of Receptors in Viral Pathogenesis,â Adv Virus Res 113 (2022): 89â110.</Citation></Reference><Reference><Citation>O. Kriger, A. Abramovich, I. S. Fratty, et al., âAn Outbreak of Coxsackievirus B Type 2 Acute Meningoencephalitis in Children, Israel, JulyâSeptember 2022,â Pediatric Infectious Disease Journal 42, no. 5 (2023): e177âe179.</Citation></Reference><Reference><Citation>M. Gullberg, C. Tolf, N. Jonsson, et al., âA Single Coxsackievirus B2 Capsid Residue Controls Cytolysis and Apoptosis in Rhabdomyosarcoma Cells,â Journal of Virology 84, no. 12 (2010): 5868â5879.</Citation></Reference><Reference><Citation>P. Chen, Z. Song, Y. Qi, et al., âMolecular Determinants of Enterovirus 71 Viral Entry,â Journal of Biological Chemistry 287, no. 9 (2012): 6406â6420.</Citation></Reference><Reference><Citation>Y. Liu, C. Wang, S. Mueller, A. V. Paul, E. Wimmer, and P. Jiang, âDirect Interaction Between Two Viral Proteins, the Nonstructural Protein 2CATPase and the Capsid Protein VP3, Is Required for Enterovirus Morphogenesis,â PLoS Pathogens 6, no. 8 (2010): e1001066.</Citation></Reference><Reference><Citation>W. A. Verstrepen, P. Bruynseels, and A. H. Mertens, âEvaluation of a Rapid RealâTime RTâPCR Assay for Detection of Enterovirus Rna in Cerebrospinal Fluid Specimens,â J Clin Virol 25 Suppl 1 (2002): S39âS43.</Citation></Reference><Reference><Citation>J. Dreier, M. StÃ¶rmer, and K. Kleesiek, âUse of Bacteriophage MS2 as an Internal Control in Viral Reverse TranscriptionâPcr Assays,â Journal of Clinical Microbiology 43, no. 9 (2005): 4551â4557.</Citation></Reference><Reference><Citation>W. A. Nix, M. S. Oberste, and M. A. Pallansch, âSensitive, Seminested Pcr Amplification of VP1 Sequences for Direct Identification of all Enterovirus Serotypes From Original Clinical Specimens,â Journal of Clinical Microbiology 44, no. 8 (2006): 2698â2704.</Citation></Reference><Reference><Citation>M. Majumdar, C. Celma, E. Pegg, K. Polra, J. Dunning, and J. Martin, âDetection and Typing of Human Enteroviruses From Clinical Samples by EntireâCapsid Next Generation Sequencing,â Viruses 13, no. 4 (2021): 641.</Citation></Reference><Reference><Citation>H. Li and R. Durbin, âFast and Accurate Short Read Alignment With BurrowsâWheeler Transform,â Bioinformatics 25, no. 14 (2009): 1754â1760.</Citation></Reference><Reference><Citation>E. F. Pettersen, T. D. Goddard, C. C. Huang, et al., âUCSF ChimeraââA Visualization System for Exploratory Research and Analysis,â Journal of Computational Chemistry 25, no. 13 (2004): 1605â1612.</Citation></Reference><Reference><Citation>M. V. Shapovalov and R. L. Dunbrack Jr., âA Smoothed BackboneâDependent Rotamer Library for Proteins Derived From Adaptive Kernel Density Estimates and Regressions,â Structure 19, no. 6 (2011): 844â858.</Citation></Reference><Reference><Citation>M. Zhang, D. Xu, C. Feng, et al., âIsolation and Characterization of a Novel Clade of Coxsackievirus B2 Associated With Hand, Foot, and Mouth Disease in Southwest China,â Journal of Medical Virology 94, no. 6 (2022): 2598â2606.</Citation></Reference><Reference><Citation>E. C. Meng, E. F. Pettersen, G. S. Couch, C. C. Huang, and T. E. Ferrin, âTools for Integrated SequenceâStructure Analysis With UCSF Chimera,â BMC Bioinformatics 7 (2006): 339.</Citation></Reference><Reference><Citation>P. Hodjat, P. A. Christensen, S. Subedi, D. W. Bernard, R. J. Olsen, and S. W. Long, âThe Reemergence of Seasonal Respiratory Viruses in Houston, Texas, After Relaxing COVIDâ19 Restrictions,â Microbiology Spectrum 9, no. 2 (2021): e0043021.</Citation></Reference><Reference><Citation>A. Kandeel, M. Fahim, O. Deghedy, et al., âResurgence of Influenza and Respiratory Syncytial Virus in Egypt Following Two Years of Decline During the COVIDâ19 Pandemic: Outpatient Clinic Survey of Infants and Children, October 2022,â BMC Public Health 23, no. 1 (2023): 1067.</Citation></Reference><Reference><Citation>I. P. Sousa Jr., R. S. Machado, F. M. Burlandy, and E. E. Silva, âDetection and Characterization of a Coxsackievirus B2 Strain Associated With Acute Meningoencephalitis, Brazil, 2018,â Revista da Sociedade Brasileira de Medicina Tropical 54 (2021): e20190499.</Citation></Reference><Reference><Citation>K. Messacar, E. SpenceâDavizon, C. Osborne, et al., âClinical Characteristics of Enterovirus A71 Neurological Disease During an Outbreak in Children in Colorado, Usa, in 2018: An Observational Cohort Study,â The Lancet Infectious Diseases 20, no. 2 (2020): 230â239.</Citation></Reference><Reference><Citation>A. Airaksinen, M. Roivainen, G. Stanway, and T. Hovi, âSiteâSaturation Mutagenesis of the Paltavetg Motif in Coxsackievirus A9 Capsid Protein VP1 Reveals Evidence of Conservation of a Periodic Hydrophobicity Profile,â Journal of General Virology 80, no. Pt 8 (1999): 1919â1927.</Citation></Reference><Reference><Citation>Protein Data Bank (PDB). Coxsackievirus B3 Coat Protein. (1996), https://www.ebi.ac.uk/pdbe/entry/pdb/1cov/analysis.</Citation></Reference><Reference><Citation>D. A. Nicholas, K. Zhang, C. Hung, et al., âPalmitic Acid Is a TollâLike Receptor 4 Ligand That Induces Human Dendritic Cell Secretion of Ilâ1Î,â Plos One 12 (2017): e0176793.</Citation></Reference><Reference><Citation>C. Polacek, J. O. EkstrÃ¶m, A. Lundgren, and A. M. Lindberg, âCytolytic Replication of Coxsackievirus B2 in CarâDeficient Rhabdomyosarcoma Cells,â Virus Research 113, no. 2 (2005): 107â115.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>